Compare SNDX & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | HLF |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2014 | 2004 |
| Metric | SNDX | HLF |
|---|---|---|
| Price | $19.58 | $12.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $38.69 | $18.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | $172,352,000.00 | ★ $5,037,500,000.00 |
| Revenue This Year | $107.19 | $4.97 |
| Revenue Next Year | $41.88 | $3.80 |
| P/E Ratio | ★ N/A | $21.31 |
| Revenue Growth | ★ 627.84 | 0.89 |
| 52 Week Low | $8.59 | $7.36 |
| 52 Week High | $25.59 | $20.40 |
| Indicator | SNDX | HLF |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 33.94 |
| Support Level | $19.28 | $11.61 |
| Resistance Level | $22.40 | $13.35 |
| Average True Range (ATR) | 0.95 | 0.69 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 15.72 | 5.71 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.